Yoram Azulay - Hadasit Bio Vice President - Finance
| HDST Stock | 53.00 0.00 0.00% |
President
Mr. Yoram Azulay serves as Vice President Finance at HBL Hadasit BioHoldings Ltd since September 20, 2015. Between August 4, 2016 and February 21, 2018 he has also served as Deputy Chief Executive Officer at the Company. His work experience includes the following roles Vice President Finance at BioLight Ltd. and Deputy Vice President Finance and investments manager at the Company. He attended Accounting and Economics studies at the Open University. since 2018.
| Age | 55 |
| Tenure | 6 years |
| Phone | 972 2 677 8757 |
| Web | https://www.hbl.co.il |
Hadasit Bio Management Efficiency
The company has return on total asset (ROA) of (0.0296) % which means that it has lost $0.0296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4387) %, meaning that it generated substantial loss on money invested by shareholders. Hadasit Bio's management efficiency ratios could be used to measure how well Hadasit Bio manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | PRESIDENT Age | ||
| Zurit Levine | Compugen | 55 | |
Management Performance
| Return On Equity | -0.44 | |||
| Return On Asset | -0.0296 |
Hadasit Bio Leadership Team
Elected by the shareholders, the Hadasit Bio's board of directors comprises two types of representatives: Hadasit Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hadasit. The board's role is to monitor Hadasit Bio's management team and ensure that shareholders' interests are well served. Hadasit Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hadasit Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yaakov Naparstek, Director | ||
| Yigal Erlich, Director | ||
| Oren Levy, Sr Director | ||
| Rob Fink, IR Contact Officer | ||
| Merav Kaye, Director | ||
| Michal Sapir, External Director | ||
| Baruch Halpert, Chairman of the Board | ||
| Alejandro Igelman, VP Fin | ||
| Doron Cohen, Internal Auditor | ||
| Michel Habib, CEO | ||
| Asaf Reisfeld, Director | ||
| Yoram Azulay, Vice President - Finance | ||
| Doron Nevo, External Director | ||
| Ophir Shahaf, CEO | ||
| Yaron Kulas, External Director | ||
| Ehud Kokia, Director | ||
| Einat Zisman, Director | ||
| Moise Habib, CEO | ||
| Tamar Raz, Director | ||
| Elka Nir, External Director | ||
| Erez Meltzer, Director | ||
| Yoram Azulai, VP CFO |
Hadasit Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hadasit Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.44 | |||
| Return On Asset | -0.0296 | |||
| Operating Margin | 0.08 % | |||
| Current Valuation | (3.4 M) | |||
| Shares Outstanding | 11.09 M | |||
| Shares Owned By Insiders | 74.99 % | |||
| Price To Book | 0.52 X | |||
| Price To Sales | 0.90 X | |||
| Gross Profit | 35.09 M | |||
| EBITDA | 28.67 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hadasit Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Hadasit Stock analysis
When running Hadasit Bio's price analysis, check to measure Hadasit Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hadasit Bio is operating at the current time. Most of Hadasit Bio's value examination focuses on studying past and present price action to predict the probability of Hadasit Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hadasit Bio's price. Additionally, you may evaluate how the addition of Hadasit Bio to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |